NATURAL FOOD IH(01837) released its annual performance, with a net profit attributable to shareholders of 2.66 billion yuan, an increase of 41.4% year-on-year.
Wugu Mofang (01837) announced its annual performance for the year ending December 31, 2025. The group achieved a revenue of 2.526 billion yuan, a year-on-year increase of 22.6%; the net profit attributable to owners of the parent company was 266 million yuan, a year-on-year increase of 41.4%; basic earnings per share were 0.122 yuan, and the proposed final dividend per ordinary share is 0.069 Hong Kong dollars.
NATURAL FOOD IH (01837) announced its annual performance as of December 31, 2025. The group recorded a total revenue of 2.526 billion yuan, an increase of 22.6% compared to the previous year. The net profit attributable to owners of the parent company stood at 266 million yuan, a year-on-year increase of 41.4%. Basic earnings per share were 0.122 yuan, and the proposed final dividend per share of ordinary shares was 0.069 Hong Kong dollars.
According to the announcement, for the fiscal year ending December 31, 2025, the group's sales revenue from both offline and online channels increased significantly compared to the fiscal year ending December 31, 2024. The offline channel business recorded a significant increase of about 31.2%, mainly due to the group's effective improvement of the operation efficiency of supermarket counter business and the successful implementation of offline shelf business development strategies.
Related Articles
SSY GROUP(02005): Upatinib has been approved by the China Food and Drug Administration for registration as an active pharmaceutical ingredient for use in marketed preparations.
HKT-SS (06823) sold approximately US$209 million for 9% equity interest in Regional Link Telecom Services Holdings Limited.
CNBM(03323): Tianshan Materials(000877.SZ) is expected to have a net loss attributable to shareholders of approximately 7.291 billion yuan in 2025, an increase of approximately 9.16 times year-on-year.
SSY GROUP(02005): Upatinib has been approved by the China Food and Drug Administration for registration as an active pharmaceutical ingredient for use in marketed preparations.
HKT-SS (06823) sold approximately US$209 million for 9% equity interest in Regional Link Telecom Services Holdings Limited.
CNBM(03323): Tianshan Materials(000877.SZ) is expected to have a net loss attributable to shareholders of approximately 7.291 billion yuan in 2025, an increase of approximately 9.16 times year-on-year.
RECOMMEND
Chinese Innovative Drug Assets Attract Major Foreign Acquisition, Cooperation Models Diversify
26/03/2026
Four Giants Subscribe As Memory Manufacturer Confirms TWD 78.718 Billion Private Placement For Capacity Expansion
26/03/2026
Year‑On‑Year Surge Exceeding 500%: Hong Kong IPOs Top HKD 100 Billion This Year
26/03/2026
